RAB39B and acute myeloid leukemia: The clinical characteristics of 150 AML patients (Table 1) retrieved from TCGA database demonstrate that RAB39B expression levels are significantly correlated with cytogenetic risk, FAB classifications (excluding the M3 type), bone marrow (BM) blast counts, and specific genetic mutations in FLT3 and NPM1.